Bruce Jaffee Ph.D. is a translational therapeutics expert with leadership experience from target discovery through preclinical development in large pharma (Novartis AG and The Du Pont Merck Pharmaceutical Company) and biotech (Millennium Pharmaceuticals and LeukoSite).
Most recently, Bruce served as the executive director at Novartis Institutes of BioMedical Research in Cambridge, Mass., with responsibility for leading drug discovery efforts in Ophthalmology. Bruce has extensive experience in inflammation, immunology, angiogenesis, autoimmunity, organ transplantation, animal model development, in vitro and in vivo pharmacology, PK/PD, surrogate marker assay development and gene therapy.
Bruce received his doctorate and master’s degree in microbiology and immunology from Drexel University College of Medicine and completed his post-doctoral training in immune regulation at the University of Colorado Medical School.